ArticleClinical, cosmetic and investigational dermatology2025
Challenges in the Treatment of Xanthoma Disseminatum: Improvement in Disfiguring Facial Lesions with Cladribine and Brief Updated Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis that falls within the spectrum of cutaneous non-Langerhans cell histiocytosis. The management of XD poses significant challenges due to the limited availability of clinical data. Here, we report a case of XD with disfiguring facial involvement that showed marked improvement following treatment with cladribine. The patient tolerated the treatment well, with no significant adverse effects observed except for a transient decrease in white blood cell count, which normalized after symptomatic treatment with appropriate oral medications. Additionally, we provide an updated review of the literature on the use of cladribine in XD. Through this case report and literature review, we aim to underscore both the potential benefits and limitations of cladribine therapy for patients with XD. Furthermore, we emphasize the critical importance of effective interdisciplinary collaboration between dermatology and oncology for the optimal management of this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.